These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29055445)

  • 1. Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβ treatment.
    Alba Palé L; León Caballero J; Samsó Buxareu B; Salgado Serrano P; Pérez Solà V
    Mult Scler Relat Disord; 2017 Oct; 17():138-143. PubMed ID: 29055445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis beyond EDSS: depression and fatigue.
    Ziemssen T
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S37-41. PubMed ID: 19200865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    Link J; Ramanujam R; Auer M; Ryner M; Hässler S; Bachelet D; Mbogning C; Warnke C; Buck D; Hyldgaard Jensen PE; Sievers C; Ingenhoven K; Fissolo N; Lindberg R; Grummel V; Donnellan N; Comabella M; Montalban X; Kieseier B; Soelberg Sørensen P; Hartung HP; Derfuss T; Lawton A; Sikkema D; Pallardy M; Hemmer B; Deisenhammer F; Broët P; Dönnes P; Davidson J; Fogdell-Hahn A;
    PLoS One; 2017; 12(2):e0170395. PubMed ID: 28170401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon β for secondary progressive multiple sclerosis: a systematic review.
    La Mantia L; Vacchi L; Rovaris M; Di Pietrantonj C; Ebers G; Fredrikson S; Filippini G
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):420-6. PubMed ID: 22952326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term emotional state of multiple sclerosis patients treated with interferon beta.
    Porcel J; Río J; Sánchez-Betancourt A; Arévalo MJ; Tintoré M; Téllez N; Borràs C; Nos C; Montalbán X
    Mult Scler; 2006 Dec; 12(6):802-7. PubMed ID: 17263010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.
    Simone IL; Ceccarelli A; Tortorella C; Bellacosa A; Pellegrini F; Plasmati I; De Caro MF; Lopez M; Girolamo F; Livrea P
    Health Qual Life Outcomes; 2006 Dec; 4():96. PubMed ID: 17163989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C; Prosperini L; Sbardella E; Paolillo A
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk of affective disorder in multiple sclerosis].
    Stenager EN; Stage KB; Stenager E
    Ugeskr Laeger; 2011 Jan; 173(2):123-6. PubMed ID: 21219844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.
    Patten SB; Francis G; Metz LM; Lopez-Bresnahan M; Chang P; Curtin F
    Mult Scler; 2005 Apr; 11(2):175-81. PubMed ID: 15794391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis.
    Matsuse D; Ochi H; Tashiro K; Nomura T; Murai H; Taniwaki T; Kira J
    Intern Med; 2005 Jan; 44(1):68-72. PubMed ID: 15704667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
    Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
    Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review.
    Balak DM; Hengstman GJ; Çakmak A; Thio HB
    Mult Scler; 2012 Dec; 18(12):1705-17. PubMed ID: 22371220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.